BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 22982977)

  • 1. NAD(P)H:quinone oxidoreductase expression in Cyp1a-knockout and CYP1A-humanized mouse lines and its effect on bioactivation of the carcinogen aristolochic acid I.
    Levova K; Moserova M; Nebert DW; Phillips DH; Frei E; Schmeiser HH; Arlt VM; Stiborova M
    Toxicol Appl Pharmacol; 2012 Dec; 265(3):360-7. PubMed ID: 22982977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of P450 1A1 and P450 1A2 in bioactivation versus detoxication of the renal carcinogen aristolochic acid I: studies in Cyp1a1-/-, Cyp1a2-/-, and Cyp1a1/1a2-/- mice.
    Arlt VM; Levová K; Bárta F; Shi Z; Evans JD; Frei E; Schmeiser HH; Nebert DW; Phillips DH; Stiborová M
    Chem Res Toxicol; 2011 Oct; 24(10):1710-9. PubMed ID: 21932800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioactivation versus detoxication of the urothelial carcinogen aristolochic acid I by human cytochrome P450 1A1 and 1A2.
    Stiborová M; Levová K; Bárta F; Shi Z; Frei E; Schmeiser HH; Nebert DW; Phillips DH; Arlt VM
    Toxicol Sci; 2012 Feb; 125(2):345-58. PubMed ID: 22086975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of cytochromes P450 1A1/2 in detoxication and activation of carcinogenic aristolochic acid I: studies with the hepatic NADPH:cytochrome P450 reductase null (HRN) mouse model.
    Levová K; Moserová M; Kotrbová V; Sulc M; Henderson CJ; Wolf CR; Phillips DH; Frei E; Schmeiser HH; Mares J; Arlt VM; Stiborová M
    Toxicol Sci; 2011 May; 121(1):43-56. PubMed ID: 21362632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of aristolochic acid I on expression of NAD(P)H:quinone oxidoreductase in mice and rats--a comparative study.
    Bárta F; Levová K; Frei E; Schmeiser HH; Arlt VM; Stiborová M
    Mutat Res Genet Toxicol Environ Mutagen; 2014 Jul; 768():1-7. PubMed ID: 24769487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Knockout and humanized mice as suitable tools to identify enzymes metabolizing the human carcinogen aristolochic acid.
    Stiborová M; Frei E; Arlt VM; Schmeiser HH
    Xenobiotica; 2014 Jan; 44(2):135-45. PubMed ID: 24152141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of cytochromes P450 in metabolism of carcinogenic aristolochic acid I: evidence of their contribution to aristolochic acid I detoxication and activation in rat liver.
    Stiborova M; Mares J; Levova K; Pavlickova J; Barta F; Hodek P; Frei E; Schmeiser HH
    Neuro Endocrinol Lett; 2011; 32 Suppl 1():121-30. PubMed ID: 22167220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of biotransformation enzymes in the development of renal injury and urothelial cancer caused by aristolochic acid: urgent questions and difficult answers.
    Stiborova M; Frei E; Arlt VM; Schmeiser HH
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2009 Mar; 153(1):5-11. PubMed ID: 19365519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of dicoumarol on the bioactivation of the carcinogen aristolochic acid I in rats.
    Stiborová M; Levová K; Bárta F; Šulc M; Frei E; Arlt VM; Schmeiser HH
    Mutagenesis; 2014 May; 29(3):189-200. PubMed ID: 24598128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human cytosolic enzymes involved in the metabolic activation of carcinogenic aristolochic acid: evidence for reductive activation by human NAD(P)H:quinone oxidoreductase.
    Stiborová M; Frei E; Sopko B; Sopková K; Marková V; Lanková M; Kumstýrová T; Wiessler M; Schmeiser HH
    Carcinogenesis; 2003 Oct; 24(10):1695-703. PubMed ID: 12869422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of activation of aristolochic acid I and II with NADPH:quinone oxidoreductase, sulphotransferases and N-acetyltranferases.
    Martinek V; Kubickova B; Arlt VM; Frei E; Schmeiser HH; Hudecek J; Stiborova M
    Neuro Endocrinol Lett; 2011; 32 Suppl 1():57-70. PubMed ID: 22167209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Theoretical investigation of differences in nitroreduction of aristolochic acid I by cytochromes P450 1A1, 1A2 and 1B1.
    Jerabek P; Martinek V; Stiborova M
    Neuro Endocrinol Lett; 2012; 33 Suppl 3():25-32. PubMed ID: 23353840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Active Site Mutations as a Suitable Tool Contributing to Explain a Mechanism of Aristolochic Acid I Nitroreduction by Cytochromes P450 1A1, 1A2 and 1B1.
    Milichovský J; Bárta F; Schmeiser HH; Arlt VM; Frei E; Stiborová M; Martínek V
    Int J Mol Sci; 2016 Feb; 17(2):213. PubMed ID: 26861298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of cytochromes P450 1A1 and 1A2 suppresses formation of DNA adducts by carcinogenic aristolochic acid I in rats in vivo.
    Dračínská H; Bárta F; Levová K; Hudecová A; Moserová M; Schmeiser HH; Kopka K; Frei E; Arlt VM; Stiborová M
    Toxicology; 2016 Feb; 344-346():7-18. PubMed ID: 26845733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enzymes metabolizing aristolochic acid and their contribution to the development of aristolochic acid nephropathy and urothelial cancer.
    Stiborová M; Martínek V; Frei E; Arlt VM; Schmeiser HH
    Curr Drug Metab; 2013 Jul; 14(6):695-705. PubMed ID: 23701164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The binding of aristolochic acid I to the active site of human cytochromes P450 1A1 and 1A2 explains their potential to reductively activate this human carcinogen.
    Stiborová M; Sopko B; Hodek P; Frei E; Schmeiser HH; Hudecek J
    Cancer Lett; 2005 Nov; 229(2):193-204. PubMed ID: 16125300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The human carcinogen aristolochic acid i is activated to form DNA adducts by human NAD(P)H:quinone oxidoreductase without the contribution of acetyltransferases or sulfotransferases.
    Stiborová M; Mareš J; Frei E; Arlt VM; Martínek V; Schmeiser HH
    Environ Mol Mutagen; 2011 Jul; 52(6):448-59. PubMed ID: 21370283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytochrome P450 1A2 detoxicates aristolochic acid in the mouse.
    Rosenquist TA; Einolf HJ; Dickman KG; Wang L; Smith A; Grollman AP
    Drug Metab Dispos; 2010 May; 38(5):761-8. PubMed ID: 20164109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baicalin Protects Mice from Aristolochic Acid I-Induced Kidney Injury by Induction of CYP1A through the Aromatic Hydrocarbon Receptor.
    Wang K; Feng C; Li C; Yao J; Xie X; Gong L; Luan Y; Xing G; Zhu X; Qi X; Ren J
    Int J Mol Sci; 2015 Jul; 16(7):16454-68. PubMed ID: 26204831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tanshinone I protects mice from aristolochic acid I-induced kidney injury by induction of CYP1A.
    Feng C; Xie X; Wu M; Li C; Gao M; Liu M; Qi X; Ren J
    Environ Toxicol Pharmacol; 2013 Nov; 36(3):850-7. PubMed ID: 23981375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.